Structure-based drug design for G protein-coupled receptors.

Our understanding of the structural biology of G protein-coupled receptors has undergone a transformation over the past 5 years. New protein-ligand complexes are described almost monthly in high profile journals. Appreciation of how small molecules and natural ligands bind to their receptors has the potential to impact enormously how medicinal chemists approach this major class of receptor targets. An outline of the key topics in this field and some recent examples of structure- and fragment-based drug design are described. A table is presented with example views of each G protein-coupled receptor for which there is a published X-ray structure, including interactions with small molecule antagonists, partial and full agonists. The possible implications of these new data for drug design are discussed.

[1]  P. Leeson,et al.  The influence of drug-like concepts on decision-making in medicinal chemistry , 2007, Nature Reviews Drug Discovery.

[2]  Miles Congreve,et al.  The impact of GPCR structures on pharmacology and structure‐based drug design , 2010, British journal of pharmacology.

[3]  V. Cherezov,et al.  Crystallizing membrane proteins using lipidic mesophases , 2009, Nature Protocols.

[4]  K. Jacobson,et al.  Truncated Nucleosides as A(3) Adenosine Receptor Ligands: Combined 2-Arylethynyl and Bicyclohexane Substitutions. , 2012, ACS medicinal chemistry letters.

[5]  J. Ballesteros,et al.  [19] Integrated methods for the construction of three-dimensional models and computational probing of structure-function relations in G protein-coupled receptors , 1995 .

[6]  C. Higgs,et al.  Hydration Site Thermodynamics Explain SARs for Triazolylpurines Analogues Binding to the A2A Receptor. , 2010, ACS medicinal chemistry letters.

[7]  Sohita Dhillon Tesamorelin , 2011, Drugs.

[8]  S. Moro,et al.  New insight into adenosine receptors selectivity derived from a novel series of [5-substituted-4-phenyl-1,3-thiazol-2-yl] benzamides and furamides. , 2013, European journal of medicinal chemistry.

[9]  S. Moro,et al.  Exploring the directionality of 5-substitutions in a new series of 5-alkylaminopyrazolo[4,3-e]1,2,4-triazolo[1,5-c]pyrimidine as a strategy to design novel human a(3) adenosine receptor antagonists. , 2012, Journal of medicinal chemistry.

[10]  R. Lefkowitz,et al.  Molecular mechanism of β-arrestin-biased agonism at seven-transmembrane receptors. , 2012, Annual review of pharmacology and toxicology.

[11]  S. Rasmussen,et al.  The structure and function of G-protein-coupled receptors , 2009, Nature.

[12]  H. Schiöth,et al.  The Adhesion GPCRs: A unique family of G protein-coupled receptors with important roles in both central and peripheral tissues , 2007, Cellular and Molecular Life Sciences.

[13]  E. Novellino,et al.  3-aryl-[1,2,4]triazino[4,3-a]benzimidazol-4(10H)-one: a novel template for the design of highly selective A₂B adenosine receptor antagonists. , 2012, Journal of medicinal chemistry.

[14]  M. Congreve,et al.  Fragment-based lead discovery , 2004, Nature Reviews Drug Discovery.

[15]  Bryan L. Roth,et al.  Structure of the human smoothened receptor bound to an antitumour agent , 2013, Nature.

[16]  Ruben Abagyan,et al.  The GPCR Network: a large-scale collaboration to determine human GPCR structure and function , 2012, Nature Reviews Drug Discovery.

[17]  E. Hulme,et al.  GPCR activation: a mutagenic spotlight on crystal structures. , 2013, Trends in pharmacological sciences.

[18]  S. Moro,et al.  Synthesis and biological evaluation of a new series of 1,2,4-triazolo[1,5-a]-1,3,5-triazines as human A(2A) adenosine receptor antagonists with improved water solubility. , 2011, Journal of medicinal chemistry.

[19]  M. Burghammer,et al.  Crystal structure of the human β2 adrenergic G-protein-coupled receptor , 2007, Nature.

[20]  M. Rosenkilde,et al.  Rational design of conformationally constrained cyclopentapeptide antagonists for C-x-C chemokine receptor 4 (CXCR4). , 2012, Journal of medicinal chemistry.

[21]  T. Schwartz,et al.  The minor binding pocket: a major player in 7TM receptor activation. , 2010, Trends in pharmacological sciences.

[22]  X. García‐Mera,et al.  Pyrimidine derivatives as potent and selective A3 adenosine receptor antagonists. , 2011, Journal of medicinal chemistry.

[23]  E. Novellino,et al.  New 2-heterocyclyl-imidazo[2,1-i]purin-5-one derivatives as potent and selective human A3 adenosine receptor antagonists. , 2011, Journal of medicinal chemistry.

[24]  S. Moro,et al.  The significance of 2-furyl ring substitution with a 2-(para-substituted) aryl group in a new series of pyrazolo-triazolo-pyrimidines as potent and highly selective hA(3) adenosine receptors antagonists: new insights into structure-affinity relationship and receptor-antagonist recognition. , 2010, Journal of medicinal chemistry.

[25]  Ruben Abagyan,et al.  Structure-based discovery of novel chemotypes for adenosine A(2A) receptor antagonists. , 2010, Journal of medicinal chemistry.

[26]  Krzysztof Palczewski,et al.  The Significance of G Protein-Coupled Receptor Crystallography for Drug Discovery , 2011, Pharmacological Reviews.

[27]  Nathan Robertson,et al.  Biophysical Mapping of the Adenosine A2A Receptor , 2011, Journal of medicinal chemistry.

[28]  Christopher G. Tate,et al.  The structural basis for agonist and partial agonist action on a β1-adrenergic receptor , 2010, Nature.

[29]  A. Gulino,et al.  Vismodegib, a small-molecule inhibitor of the hedgehog pathway for the treatment of advanced cancers. , 2010, Current opinion in investigational drugs.

[30]  Jonathan S. Mason,et al.  Progress in Structure Based Drug Design for G Protein-Coupled Receptors , 2011, Journal of medicinal chemistry.

[31]  Anthony J Harmar,et al.  Family-B G-protein-coupled receptors , 2001, Genome Biology.

[32]  Gregg Siegal,et al.  Fragment screening of GPCRs using biophysical methods: identification of ligands of the adenosine A(2A) receptor with novel biological activity. , 2012, ACS chemical biology.

[33]  Bryan L. Roth,et al.  Structure of the human kappa opioid receptor in complex with JDTic , 2012, Nature.

[34]  Sid Topiol,et al.  Use of the X-ray structure of the Beta2-adrenergic receptor for drug discovery. , 2008, Bioorganic & medicinal chemistry letters.

[35]  Amy M. Fulton,et al.  The chemokine receptors CXCR4 and CXCR3 in cancer , 2009, Current oncology reports.

[36]  C. Langmead,et al.  Pharmacology and Structure of Isolated Conformations of the Adenosine A2A Receptor Define Ligand Efficacy , 2013, Molecular Pharmacology.

[37]  R. Stevens,et al.  Recent progress in the structure determination of GPCRs, a membrane protein family with high potential as pharmaceutical targets. , 2010, Methods in molecular biology.

[38]  J. Holst,et al.  Treatment of adult short bowel syndrome patients with teduglutide , 2012, Expert opinion on pharmacotherapy.

[39]  G. Marucci,et al.  Molecular modeling study on potent and selective adenosine A(3) receptor agonists. , 2010, Bioorganic & medicinal chemistry.

[40]  C. Tate,et al.  Thermostabilisation of an Agonist-Bound Conformation of the Human Adenosine A2A Receptor , 2011, Journal of molecular biology.

[41]  R. Abagyan,et al.  Molecular mechanisms deployed by virally encoded G protein-coupled receptors in human diseases. , 2013, Annual review of pharmacology and toxicology.

[42]  R. Stevens,et al.  Structural Features for Functional Selectivity at Serotonin Receptors , 2013, Science.

[43]  T. O'Brien,et al.  Fragment-based drug discovery. , 2004, Journal of medicinal chemistry.

[44]  R. Stevens,et al.  Crystal structure-based virtual screening for fragment-like ligands of the human histamine H(1) receptor. , 2011, Journal of medicinal chemistry.

[45]  M. Caron,et al.  The mammalian beta 2-adrenergic receptor: reconstitution of functional interactions between pure receptor and pure stimulatory nucleotide binding protein of the adenylate cyclase system. , 1984, Biochemistry.

[46]  Miles Congreve,et al.  Deal watch: Valuation benefits of structure-enabled drug discovery , 2011, Nature Reviews Drug Discovery.

[47]  Francesca Deflorian,et al.  Structure-guided design of A(3) adenosine receptor-selective nucleosides: combination of 2-arylethynyl and bicyclo[3.1.0]hexane substitutions. , 2012, Journal of medicinal chemistry.

[48]  M. Congreve,et al.  Structure of the adenosine A(2A) receptor in complex with ZM241385 and the xanthines XAC and caffeine. , 2011, Structure.

[49]  Jonathan A. Javitch,et al.  Structure of the Human Dopamine D3 Receptor in Complex with a D2/D3 Selective Antagonist , 2010, Science.

[50]  Ruben Abagyan,et al.  Optimization of adenosine 5'-carboxamide derivatives as adenosine receptor agonists using structure-based ligand design and fragment screening. , 2012, Journal of medicinal chemistry.

[51]  K. Jacobson,et al.  Structure-activity relationships of truncated C2- or C8-substituted adenosine derivatives as dual acting A₂A and A₃ adenosine receptor ligands. , 2012, Journal of medicinal chemistry.

[52]  C. Tate,et al.  Agonist-bound structures of G protein-coupled receptors. , 2012, Current opinion in structural biology.

[53]  Hualiang Jiang,et al.  Structural Basis for Molecular Recognition at Serotonin Receptors , 2013, Science.

[54]  N. Fujii,et al.  Molecular modeling study of cyclic pentapeptide CXCR4 antagonists: new insight into CXCR4-FC131 interactions. , 2012, Bioorganic & medicinal chemistry letters.

[55]  Christopher G Tate,et al.  A crystal clear solution for determining G-protein-coupled receptor structures. , 2012, Trends in biochemical sciences.

[56]  Brian K. Shoichet,et al.  Structure-Based Discovery of A2A Adenosine Receptor Ligands , 2010, Journal of medicinal chemistry.

[57]  J. Mestres,et al.  New chromene scaffolds for adenosine A(2A) receptors: synthesis, pharmacology and structure-activity relationships. , 2012, European journal of medicinal chemistry.

[58]  A. Hopkins,et al.  Ligand efficiency: a useful metric for lead selection. , 2004, Drug discovery today.

[59]  S. Mudaliar,et al.  Evolution of Exenatide as a Diabetes Therapeutic , 2013, Current diabetes reviews.

[60]  Andreas Bender,et al.  A prospective cross-screening study on G-protein-coupled receptors: lessons learned in virtual compound library design. , 2012, Journal of medicinal chemistry.

[61]  S. Moro,et al.  2-Arylpyrazolo[4,3-d]pyrimidin-7-amino derivatives as new potent and selective human A3 adenosine receptor antagonists. Molecular modeling studies and pharmacological evaluation. , 2013, Journal of medicinal chemistry.

[62]  David Rodríguez,et al.  Selective and potent adenosine A3 receptor antagonists by methoxyaryl substitution on the N-(2,6-diarylpyrimidin-4-yl)acetamide scaffold. , 2013, European journal of medicinal chemistry.

[63]  Z. Liu,et al.  Structure-based design in the GPCR target space. , 2012, Current Medicinal Chemistry.

[64]  Charles L. Brooks,et al.  Community-wide assessment of GPCR structure modelling and ligand docking: GPCR Dock 2008 , 2009, Nature Reviews Drug Discovery.

[65]  Hugo Gutiérrez-de-Terán,et al.  Ligand-, structure- and pharmacophore-based molecular fingerprints: a case study on adenosine A1, A2A, A2B, and A3 receptor antagonists , 2012, Journal of Computer-Aided Molecular Design.

[66]  Krzysztof Palczewski,et al.  Vertebrate Membrane Proteins: Structure, Function, and Insights from Biophysical Approaches , 2008, Pharmacological Reviews.

[67]  J. Tyndall,et al.  GPCR agonists and antagonists in the clinic. , 2005, Medicinal chemistry (Shariqah (United Arab Emirates)).

[68]  Ali Jazayeri,et al.  Structure of class B GPCR corticotropin-releasing factor receptor 1 , 2013, Nature.

[69]  L. Pardo,et al.  Crystal structure of the μ-opioid receptor bound to a morphinan antagonist , 2012, Nature.

[70]  Jens Carlsson,et al.  Structure-activity relationships and molecular modeling of 1,2,4-triazoles as adenosine receptor antagonists. , 2012, ACS medicinal chemistry letters.

[71]  R. Stevens,et al.  High-Resolution Crystal Structure of an Engineered Human β2-Adrenergic G Protein–Coupled Receptor , 2007, Science.

[72]  Christopher G. Tate,et al.  Biophysical Fragment Screening of the β1-Adrenergic Receptor: Identification of High Affinity Arylpiperazine Leads Using Structure-Based Drug Design , 2013, Journal of medicinal chemistry.

[73]  G. Schulte,et al.  The Frizzled family of unconventional G-protein-coupled receptors. , 2007, Trends in pharmacological sciences.

[74]  W. Danysz,et al.  Metabotropic glutamate receptors as therapeutic targets for cognitive disorders. , 2010, Current topics in medicinal chemistry.

[75]  Cheng Zhang,et al.  High-resolution Crystal Structure of Human Protease-activated Receptor 1 Bound to the Antagonist Vorapaxar Hhs Public Access , 2022 .

[76]  S. P. Andrews,et al.  Stabilised G protein-coupled receptors in structure-based drug design: a case study with adenosine A2A receptor , 2013 .

[77]  T. Dinan,et al.  Exciting Times beyond the Brain: Metabotropic Glutamate Receptors in Peripheral and Non-Neural Tissues , 2011, Pharmacological Reviews.

[78]  John P. Overington,et al.  How many drug targets are there? , 2006, Nature Reviews Drug Discovery.

[79]  Albert C. Pan,et al.  Structure and Dynamics of the M3 Muscarinic Acetylcholine Receptor , 2012, Nature.

[80]  Martin Caffrey,et al.  Membrane protein structure determination using crystallography and lipidic mesophases: recent advances and successes. , 2012, Biochemistry.

[81]  Aashish Manglik,et al.  Structure of the δ-opioid receptor bound to naltrindole , 2012, Nature.

[82]  R. Stevens,et al.  Structure-function of the G protein-coupled receptor superfamily. , 2013, Annual review of pharmacology and toxicology.

[83]  Christopher G. Tate,et al.  Crystal Structures of a Stabilized β1-Adrenoceptor Bound to the Biased Agonists Bucindolol and Carvedilol , 2012, Structure.

[84]  Ruben Abagyan,et al.  GPCR agonist binding revealed by modeling and crystallography. , 2011, TIPS - Trends in Pharmacological Sciences.

[85]  D. Scott,et al.  Fragment-based approaches in drug discovery and chemical biology. , 2012, Biochemistry.

[86]  S. Rasmussen,et al.  A monoclonal antibody for G protein–coupled receptor crystallography , 2007, Nature Methods.

[87]  A. Oxford,et al.  The Pharmacology of the Novel 5-HT1-Like Receptor Agonist, GR43175 , 1989, Cephalalgia : an international journal of headache.

[88]  Tom L. Blundell,et al.  Keynote review: Structural biology and drug discovery , 2005 .

[89]  W. Delano The PyMOL Molecular Graphics System , 2002 .

[90]  Peter Kolb,et al.  Limits of Ligand Selectivity from Docking to Models: In Silico Screening for A1 Adenosine Receptor Antagonists , 2012, PloS one.

[91]  R. Stevens,et al.  Structural Basis for Allosteric Regulation of GPCRs by Sodium Ions , 2012, Science.

[92]  D. Rognan,et al.  Selective structure-based virtual screening for full and partial agonists of the beta2 adrenergic receptor. , 2008, Journal of medicinal chemistry.

[93]  J. Shiloach,et al.  Structure of the agonist-bound neurotensin receptor , 2012, Nature.

[94]  M. Congreve,et al.  Recent developments in fragment-based drug discovery. , 2008, Journal of medicinal chemistry.

[95]  A. Kruse,et al.  Structure of the human M2 muscarinic acetylcholine receptor bound to an antagonist , 2011, Nature.

[96]  G. Pairaudeau,et al.  Design driven HtL: The discovery and synthesis of new high efficacy β₂-agonists. , 2011, Bioorganic & medicinal chemistry letters.

[97]  N. Neamati,et al.  Design of a novel cyclotide-based CXCR4 antagonist with anti-human immunodeficiency virus (HIV)-1 activity. , 2012, Journal of medicinal chemistry.

[98]  X. Deupí,et al.  Conserved activation pathways in G-protein-coupled receptors. , 2012, Biochemical Society transactions.

[99]  B. Roth,et al.  NOBEL 2012 Chemistry: Studies of a ubiquitous receptor family , 2012, Nature.

[100]  E. Uriarte,et al.  Discovery of novel A3 adenosine receptor ligands based on chromone scaffold. , 2012, Biochemical pharmacology.

[101]  R. Abagyan,et al.  Conserved binding mode of human beta2 adrenergic receptor inverse agonists and antagonist revealed by X-ray crystallography. , 2010, Journal of the American Chemical Society.

[102]  Gregg Siegal,et al.  Fragment screening of stabilized G-protein-coupled receptors using biophysical methods. , 2011, Methods in enzymology.

[103]  S. Keam,et al.  Teriparatide: a review of its use in osteoporosis. , 2008, Drugs.

[104]  R. Rothman,et al.  Serotonergic drugs and valvular heart disease , 2009, Expert opinion on drug safety.

[105]  W. Spooren,et al.  Allosteric Modulators for mGlu Receptors , 2007, Current neuropharmacology.

[106]  Yoko Shibata,et al.  Conformational thermostabilization of the β1-adrenergic receptor in a detergent-resistant form , 2008, Proceedings of the National Academy of Sciences.

[107]  Dov Barak,et al.  Evaluation of homology modeling of G-protein-coupled receptors in light of the A(2A) adenosine receptor crystallographic structure. , 2009, Journal of medicinal chemistry.

[108]  Sébastien Granier,et al.  A new era of GPCR structural and chemical biology. , 2012, Nature chemical biology.

[109]  A. Bender,et al.  Substructure‐Based Virtual Screening for Adenosine A2A Receptor Ligands , 2011, ChemMedChem.

[110]  S. Rasmussen,et al.  Structure of a nanobody-stabilized active state of the β2 adrenoceptor , 2010, Nature.

[111]  Hugh Rosen,et al.  Crystal Structure of a Lipid G Protein–Coupled Receptor , 2012, Science.

[112]  Yoko Shibata,et al.  Thermostabilisation of the neurotensin receptor NTS1 , 2009, Journal of molecular biology.

[113]  Oliver P. Ernst,et al.  Crystal structure of opsin in its G-protein-interacting conformation , 2008, Nature.

[114]  P. Conn,et al.  Metabotropic glutamate receptors: physiology, pharmacology, and disease. , 2010, Annual review of pharmacology and toxicology.

[115]  Ruben Abagyan,et al.  Structure of the human histamine H1 receptor complex with doxepin , 2011, Nature.

[116]  H. V. van Vlijmen,et al.  Identifying novel adenosine receptor ligands by simultaneous proteochemometric modeling of rat and human bioactivity data. , 2012, Journal of medicinal chemistry.

[117]  Bryan L. Roth,et al.  Structure of the Nociceptin/Orphanin FQ Receptor in Complex with a Peptide Mimetic , 2012, Nature.

[118]  K. Varani,et al.  Pyrazolo[1,5-c]quinazoline derivatives and their simplified analogues as adenosine receptor antagonists: synthesis, structure-affinity relationships and molecular modeling studies. , 2013, Bioorganic & medicinal chemistry.

[119]  Jonathan S. Mason,et al.  Discovery of 1,2,4-Triazine Derivatives as Adenosine A2A Antagonists using Structure Based Drug Design , 2012, Journal of medicinal chemistry.

[120]  Raymond C Stevens,et al.  Discovery of new GPCR biology: one receptor structure at a time. , 2009, Structure.

[121]  Steven M. Moss,et al.  Structural sweet spot for A1 adenosine receptor activation by truncated (N)-methanocarba nucleosides: receptor docking and potent anticonvulsant activity. , 2012, Journal of medicinal chemistry.

[122]  Gebhard F. X. Schertler,et al.  Structure of a β1-adrenergic G-protein-coupled receptor , 2008, Nature.

[123]  Bernhard Moser,et al.  The CXC chemokine SDF-1 is the ligand for LESTR/fusin and prevents infection by T-cell-line-adapted HIV-1 , 1996, Nature.

[124]  J. Errey,et al.  Preparation of purified GPCRs for structural studies. , 2013, Biochemical Society transactions.

[125]  Chris de Graaf,et al.  Structure of the human glucagon class B G-protein-coupled receptor , 2013, Nature.

[126]  Xavier Deupi,et al.  Structural insights into agonist-induced activation of G-protein-coupled receptors. , 2011, Current opinion in structural biology.

[127]  Guodong Liu,et al.  A G Protein-Biased Ligand at the μ-Opioid Receptor Is Potently Analgesic with Reduced Gastrointestinal and Respiratory Dysfunction Compared with Morphine , 2013, The Journal of Pharmacology and Experimental Therapeutics.

[128]  R. Abagyan,et al.  Structures of the CXCR4 Chemokine GPCR with Small-Molecule and Cyclic Peptide Antagonists , 2010, Science.

[129]  M. Babu,et al.  Molecular signatures of G-protein-coupled receptors , 2013, Nature.

[130]  Peter Kolb,et al.  Structure-based discovery of β2-adrenergic receptor ligands , 2009, Proceedings of the National Academy of Sciences.

[131]  S. Moro,et al.  Synthesis and pharmacological characterization of a new series of 5,7-disubstituted-[1,2,4]triazolo[1,5-a][1,3,5]triazine derivatives as adenosine receptor antagonists: A preliminary inspection of ligand-receptor recognition process. , 2010, Bioorganic & medicinal chemistry.

[132]  H. Jhoti,et al.  A new school for screening , 2005, Nature Biotechnology.

[133]  R. Stevens,et al.  The 2.6 Angstrom Crystal Structure of a Human A2A Adenosine Receptor Bound to an Antagonist , 2008, Science.

[134]  José Correa-Basurto,et al.  Cell-based and in-silico studies on the high intrinsic activity of two boron-containing salbutamol derivatives at the human β₂-adrenoceptor. , 2012, Bioorganic & medicinal chemistry.

[135]  Nathan Robertson,et al.  Article pubs.acs.org/jmc Identification of Novel Adenosine A 2A Receptor Antagonists by Virtual Screening , 2022 .

[136]  T. Kenakin Principles: receptor theory in pharmacology. , 2004, Trends in pharmacological sciences.

[137]  Christopher W Murray,et al.  Experiences in fragment-based drug discovery. , 2012, Trends in pharmacological sciences.

[138]  Nobuhiro Yamamoto,et al.  Discovery of highly potent and selective biphenylacylsulfonamide-based beta3-adrenergic receptor agonists and molecular modeling based on the solved X-ray structure of the beta2-adrenergic receptor: part 6. , 2009, Bioorganic & medicinal chemistry letters.

[139]  Minyong Li,et al.  Revisiting the homology modeling of G-protein coupled receptors: β1-adrenoceptor as an example. , 2012, Molecular bioSystems.

[140]  Kenneth Jones,et al.  Use of the X-ray structure of the beta2-adrenergic receptor for drug discovery. Part 2: Identification of active compounds. , 2008, Bioorganic & medicinal chemistry letters.

[141]  S. Costanzi Modeling G protein-coupled receptors and their interactions with ligands. , 2013, Current opinion in structural biology.

[142]  Fei Xu,et al.  Evaluation of molecular modeling of agonist binding in light of the crystallographic structure of an agonist-bound A₂A adenosine receptor. , 2012, Journal of medicinal chemistry.

[143]  R. Stevens,et al.  Structure of an Agonist-Bound Human A2A Adenosine Receptor , 2011, Science.

[144]  Andrea Bortolato,et al.  New insights from structural biology into the druggability of G protein-coupled receptors. , 2012, Trends in pharmacological sciences.

[145]  Reuben J Pengelly,et al.  Fragment Screening Using Capillary Electrophoresis (CEfrag) for Hit Identification of Heat Shock Protein 90 ATPase Inhibitors , 2012, Journal of biomolecular screening.

[146]  Nathan Robertson,et al.  The properties of thermostabilised G protein-coupled receptors (StaRs) and their use in drug discovery , 2011, Neuropharmacology.

[147]  Stefano Costanzi,et al.  Chapter 18:Structure-based Virtual Screening for Ligands of G Protein-coupled Receptors , 2011 .

[148]  Patrick Scheerer,et al.  Crystal structure of the ligand-free G-protein-coupled receptor opsin , 2008, Nature.

[149]  Vadim Cherezov,et al.  Diversity and modularity of G protein-coupled receptor structures. , 2012, Trends in pharmacological sciences.

[150]  S. Rasmussen,et al.  Crystal Structure of the β2Adrenergic Receptor-Gs protein complex , 2011, Nature.

[151]  Yoko Shibata,et al.  Co-evolving stability and conformational homogeneity of the human adenosine A2a receptor , 2008, Proceedings of the National Academy of Sciences.

[152]  A. Leslie,et al.  Agonist-bound adenosine A2A receptor structures reveal common features of GPCR activation , 2011, Nature.

[153]  S. Moro,et al.  2-Phenylpyrazolo[4,3-d]pyrimidin-7-one as a new scaffold to obtain potent and selective human A3 adenosine receptor antagonists: new insights into the receptor-antagonist recognition. , 2009, Journal of medicinal chemistry.

[154]  Michèle N Schulz,et al.  Recent progress in fragment-based lead discovery. , 2009, Current opinion in pharmacology.

[155]  J. Black Drugs from emasculated hormones: the principle of syntopic antagonism. , 1989, Bioscience reports.

[156]  K. Jacobson,et al.  New Insights for Drug Design from the X-Ray Crystallographic Structures of G-Protein-Coupled Receptors , 2012, Molecular Pharmacology.

[157]  Brian K Shoichet,et al.  Structure-based drug screening for G-protein-coupled receptors. , 2012, Trends in pharmacological sciences.

[158]  Monya Baker,et al.  Fragment-based lead discovery grows up , 2012, Nature Reviews Drug Discovery.

[159]  K. Jacobson Structure-based approaches to ligands for G-protein-coupled adenosine and P2Y receptors, from small molecules to nanoconjugates. , 2013, Journal of medicinal chemistry.